Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Karuna Therapeutics, Inc. (KRTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Karuna Therapeutics Reports Second Quarter 2023 Financial Results and Provides General Business Updates On track to submit New Drug Application for KarXT in schizophrenia with the U.S. FDA in the third quarter of 2023, with a product launch in the second half of 2024, assuming approval Initiated the Phase 3 ADEPT-3 open label extension trial in the third quarter of 2023, and on track to commence the Phase 3 ADEPT-2 trial in the second half of 2023 Announced the appointment of Jonathan Rosin to Chief Human Resources Officer and the promotion of Jason Brown to Chief Financial Officer $1.4 billion in cash expected to fund operations through 2026 Conference call and webcast to take place today at 8:00 a.m. ET"
05/04/2023 8-K Quarterly results
03/22/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Karuna Therapeutics, Inc.Common Stock, par value $0.0001 per share _________ Underwriting Agreement March 21, 2023 Goldman Sachs & Co. LLCJ.P. Morgan Securities LLC Morgan Stanley & Co. LLC As representatives of the several Underwritersnamed in Schedule I hereto c/o Goldman Sachs & Co. LLC200 West StreetNew York, New York 10282",
"Registration Statement”) filed on July 2, 2020 with the Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended , relating to the registration of the offer by Karuna Therapeutics, Inc., a Delaware corporation of an indeterminate number of any combination of securities of the types specified therein. The Registration Statement became effective upon filing with the Commission. Reference is made to our opinion letter dated July 2, 2020 and included as Exhibit 5.1 to the Registration Statement. We are delivering this supplemental opinion letter in connection with the prospectus supplement (the “Prospectus Supplement",
"Karuna Therapeutics Announces Proposed Public Offering of Common Stock",
"Karuna Therapeutics Announces Pricing of Public Offering of Common Stock"
03/20/2023 8-K Quarterly results
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
02/23/2023 8-K Quarterly results
Docs: "Karuna Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Result and Provides General Business Updates Topline data from Phase 3 EMERGENT-3 trial anticipated in the first quarter of 2023 On track to submit New Drug Application for KarXT in schizophrenia to the U.S. Food & Drug Administration in mid-2023 Announced exclusive global license agreement for investigational TRPC4/5 inhibitors, including lead clinical-stage candidate KAR-2618 , in the first quarter of 2023 $1.1 billion in cash is expected to fund operations through the end of 2025"
02/02/2023 8-K Quarterly results
01/05/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/06/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
02/24/2022 8-K Quarterly results
02/24/2022 8-K Quarterly results
12/22/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
11/09/2021 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China"
11/04/2021 8-K Quarterly results
Docs: "Karuna Therapeutics Reports Third Quarter 2021 Financial Results and Provides General Business Update Topline data from the Phase 3 EMERGENT-2 and EMERGENT-3 trials expected in mid-2022 and in the second half of 2022, respectively On track to initiate the Phase 3 ARISE trial evaluating KarXT in adults with schizophrenia who inadequately respond to current standard of care in the fourth quarter of 2021 Company plans to initiate a Phase 3 program evaluating KarXT for the treatment of psychosis in elderly patients with Alzheimer’s disease in mid-2022 $498.9 million in cash expected to fund operations, including multiple milestones, for at least 12 months following the potential New Drug Application submission of KarXT in schizophrenia"
08/05/2021 8-K Quarterly results
06/23/2021 8-K Quarterly results
06/21/2021 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/06/2021 8-K Quarterly results
03/10/2021 8-K Quarterly results
03/03/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
12/22/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 22, 2020 KARUNA THERAPEUTICS, INC. Delaware 001-38958 27-0605902 33 Arch Street, Suite 3110 Boston, Massachusetts 02110 Registrant's telephone number, including area code: 449-2244 Not Applicable Former name or former address, if changed since last report Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement com...",
"Karuna Therapeutics Appoints Denice Torres, J.D., to its Board of Directors"
12/03/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 3, 2020 KARUNA THERAPEUTICS, INC. Delaware 001-38958 27-0605902 33 Arch Street, Suite 3110 Boston, Massachusetts 02110 Registrant's telephone number, including area code: 449-2244 Not Applicable Former name or former address, if changed since last report Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement comm...",
"Karuna Therapeutics Appoints David Wheadon, M.D., to its Board of Directors"
11/05/2020 8-K Quarterly results
Docs: "Karuna Therapeutics Reports Third Quarter 2020 Financial Results and Provides General Business Update"
10/13/2020 8-K Quarterly results
10/07/2020 8-K Quarterly results
08/13/2020 8-K Quarterly results
08/05/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy